Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%
Market cap
$3.6B
P/E
29.9×
Fwd P/E
45.1×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
40.78 29.02 50.12 88.03

+8 more quarters

P/S ratio
8.36 4.73 6.40 5.46
P/FCF ratio
28.30 16.49 26.13 27.52
P/Operating CF
102.49 72.75 62.92 60.38
P/B ratio
3.38 1.91 2.53 2.15
EV/Sales
7.50 3.92 5.60 4.72
EV/EBITDA
34.00 22.14 38.17 52.96
EV/FCF
25.39 13.68 22.88 23.81
Current Ratio
9.16 9.31 8.15 6.23
Net Debt/EBITDA
(17.91) (15.99) (9.87) (13.31)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
2.45% 3.45% 2.00% 1.14%
Free Cash Flow Yield
3.53% 6.06% 3.83% 3.63%
Free Cash Flow per Share
0.54 0.41 0.62 0.53
Book value per Share
17.36 16.90 16.66 15.98
Free Cash Flow
42.97 32.25 48.80 41.97
EV/EBIT
39.84 27.41 50.15 94.46
Other line items

Show all line items

Columns are period end dates